Thomas Giles

Summary

Country: USA

Publications

  1. doi request reprint Comparative efficacy of aliskiren/valsartan vs valsartan in nocturnal dipper and nondipper hypertensive patients: a pooled analysis
    Thomas D Giles
    Heart and Vascular Institute, Tulane University School of Medicine, New Orleans, LA 70005, USA
    J Clin Hypertens (Greenwich) 14:299-306. 2012
  2. doi request reprint Impaired vasodilation in the pathogenesis of hypertension: focus on nitric oxide, endothelial-derived hyperpolarizing factors, and prostaglandins
    Thomas D Giles
    Heart and Vascular Institute, Tulane University Medical Center, New Orleans, LA, USA
    J Clin Hypertens (Greenwich) 14:198-205. 2012
  3. ncbi request reprint Effects of thiazolidinediones on blood pressure
    Thomas D Giles
    Section of Cardiology, Department of Medicine, Tulane University School of Medicine, 1430 Tulane Avenue, New Orleans, LA 70112, USA
    Curr Hypertens Rep 9:332-7. 2007
  4. doi request reprint Definition and classification of hypertension: an update
    Thomas D Giles
    Tulane University School of Medicine, Metairie, LA 7005, USA
    J Clin Hypertens (Greenwich) 11:611-4. 2009
  5. doi request reprint Comparison of pioglitazone vs glyburide in early heart failure: insights from a randomized controlled study of patients with type 2 diabetes and mild cardiac disease
    Thomas D Giles
    Tulane University School of Medicine, New Orleans, LA, USA
    Congest Heart Fail 16:111-7. 2010
  6. doi request reprint The role of vasodilating beta-blockers in patients with complicated hypertension: focus on nebivolol
    Thomas D Giles
    Department of Medicine, Tulane University School of Medicine, New Orleans, Louisiana, USA
    Am J Med 123:S16-20. 2010
  7. ncbi request reprint Ethnic/racial variations in blood pressure awareness, treatment, and control
    Thomas Giles
    Tulane University School of Medicine, New Orleans, LA, USA
    J Clin Hypertens (Greenwich) 9:345-54. 2007
  8. ncbi request reprint Circadian rhythm of blood pressure and the relation to cardiovascular events
    Thomas D Giles
    Louisiana State University Health Sciences Center, New Orleans, 70112, USA
    J Hypertens Suppl 24:S11-6. 2006
  9. ncbi request reprint The Trial of Preventing Hypertension (TROPHY) as seen through the eyes of the Hypertension Writing Group's expanded definition of hypertension
    Thomas D Giles
    Department of Medicine, Louisiana State University Medical Center, New Orleans, LA 70112, USA
    J Clin Hypertens (Greenwich) 8:441-3. 2006
  10. ncbi request reprint Aspects of nitric oxide in health and disease: a focus on hypertension and cardiovascular disease
    Thomas D Giles
    Division of Cardiology, Tulane University School of Medicine, New Orleans, LA, USA
    J Clin Hypertens (Greenwich) 8:2-16. 2006

Research Grants

Detail Information

Publications81

  1. doi request reprint Comparative efficacy of aliskiren/valsartan vs valsartan in nocturnal dipper and nondipper hypertensive patients: a pooled analysis
    Thomas D Giles
    Heart and Vascular Institute, Tulane University School of Medicine, New Orleans, LA 70005, USA
    J Clin Hypertens (Greenwich) 14:299-306. 2012
    ..Although the addition of aliskiren to valsartan did not significantly alter dipper status, our data suggest an increased contribution of the renin-angiotensin-aldosterone system to the nondipper status of hypertensive patients...
  2. doi request reprint Impaired vasodilation in the pathogenesis of hypertension: focus on nitric oxide, endothelial-derived hyperpolarizing factors, and prostaglandins
    Thomas D Giles
    Heart and Vascular Institute, Tulane University Medical Center, New Orleans, LA, USA
    J Clin Hypertens (Greenwich) 14:198-205. 2012
    ..Possible pharmacological interventions to restore normal function are suggested...
  3. ncbi request reprint Effects of thiazolidinediones on blood pressure
    Thomas D Giles
    Section of Cardiology, Department of Medicine, Tulane University School of Medicine, 1430 Tulane Avenue, New Orleans, LA 70112, USA
    Curr Hypertens Rep 9:332-7. 2007
    ..A significant proportion of patients with type 2 diabetes mellitus and BP mildly above target range might be successfully treated for both processes with a single drug...
  4. doi request reprint Definition and classification of hypertension: an update
    Thomas D Giles
    Tulane University School of Medicine, Metairie, LA 7005, USA
    J Clin Hypertens (Greenwich) 11:611-4. 2009
    ..This paper discusses the logic underlying the refinements in the definition of hypertension...
  5. doi request reprint Comparison of pioglitazone vs glyburide in early heart failure: insights from a randomized controlled study of patients with type 2 diabetes and mild cardiac disease
    Thomas D Giles
    Tulane University School of Medicine, New Orleans, LA, USA
    Congest Heart Fail 16:111-7. 2010
    ..2% vs 12.8%), and weight gain (2.56+/-4.62 kg vs 0.86+/-3.85 kg) were observed than with glyburide...
  6. doi request reprint The role of vasodilating beta-blockers in patients with complicated hypertension: focus on nebivolol
    Thomas D Giles
    Department of Medicine, Tulane University School of Medicine, New Orleans, Louisiana, USA
    Am J Med 123:S16-20. 2010
    ..g., elderly patients, African American patients), a vasodilating beta-blocker may be a particularly appropriate choice for these patient groups...
  7. ncbi request reprint Ethnic/racial variations in blood pressure awareness, treatment, and control
    Thomas Giles
    Tulane University School of Medicine, New Orleans, LA, USA
    J Clin Hypertens (Greenwich) 9:345-54. 2007
    ..Effective interventions targeting Mexican Americans and blacks as well as whites are essential to improving hypertension management...
  8. ncbi request reprint Circadian rhythm of blood pressure and the relation to cardiovascular events
    Thomas D Giles
    Louisiana State University Health Sciences Center, New Orleans, 70112, USA
    J Hypertens Suppl 24:S11-6. 2006
    ....
  9. ncbi request reprint The Trial of Preventing Hypertension (TROPHY) as seen through the eyes of the Hypertension Writing Group's expanded definition of hypertension
    Thomas D Giles
    Department of Medicine, Louisiana State University Medical Center, New Orleans, LA 70112, USA
    J Clin Hypertens (Greenwich) 8:441-3. 2006
  10. ncbi request reprint Aspects of nitric oxide in health and disease: a focus on hypertension and cardiovascular disease
    Thomas D Giles
    Division of Cardiology, Tulane University School of Medicine, New Orleans, LA, USA
    J Clin Hypertens (Greenwich) 8:2-16. 2006
    ..Other cardiovascular therapies that may improve NO bioactivity include statins, l-arginine, and nonpharmacologic approaches such as exercise and dietary changes...
  11. ncbi request reprint Should we redefine hypertension?
    Thomas D Giles
    Department of Medicine, Tulane University School of Medicine, 109 Holly Drive, Metairie, LA 70005, USA
    Curr Cardiol Rep 8:395-8. 2006
    ..This definition of hypertension will permit physicians to treat patients with the goal of reducing global risk for myocardial infarction, stroke, and chronic kidney disease...
  12. ncbi request reprint Comparison of increasing doses of olmesartan medoxomil, losartan potassium, and valsartan in patients with essential hypertension
    Thomas D Giles
    Tulane University School of Medicine, New Orleans, LA 70005, USA
    J Clin Hypertens (Greenwich) 9:187-95. 2007
    ..001). Olmesartan did not reduce mean SeDBP significantly compared with valsartan, although more patients attained blood pressure goal with olmesartan (P=.031). At week 12, all agents lowered blood pressure equivalently...
  13. doi request reprint The role of ambulatory blood pressure monitoring compared with clinic and home blood pressure measures in evaluating moderate versus intensive treatment of hypertension with amlodipine/valsartan for patients uncontrolled on angiotensin receptor blocker mo
    Thomas D Giles
    Tulane University School of Medicine, New Orleans, Louisiana, USA
    Blood Press Monit 16:87-95. 2011
    ..Home BP was measured on the morning of clinic visits to minimize differences that timing might have on home versus office BP measures...
  14. ncbi request reprint Assessment of global risk: a foundation for a new, better definition of hypertension
    Thomas D Giles
    Tulane University School of Medicine, New Orleans, LA, USA
    J Clin Hypertens (Greenwich) 8:5-14; quiz 39. 2006
    ..This revision of the definition of hypertension and the need to assess BP levels in the context of global cardiovascular risk should lead to earlier detection of at-risk patients...
  15. doi request reprint The role of nitric oxide in improving endothelial function and cardiovascular health: focus on nebivolol
    George L Bakris
    Hypertensive Diseases Unit, Department of Medicine, University of Chicago Medical Center, Chicago, Illinois, USA
    Am J Med 123:S2-8. 2010
    ....
  16. pmc Stimulus response of blood pressure in black and white young individuals helps explain racial divergence in adult cardiovascular disease: the Bogalusa Heart Study
    Gerald S Berenson
    Tulane Center for Cardiovascular Health, New Orleans, LA, USA
    J Am Soc Hypertens 5:230-8. 2011
    ..Taken together, understanding racial (black-white) contrasts to stress contribute to both prevention and treatment of hypertension, especially for black males...
  17. doi request reprint Prevention of type 2 diabetes mellitus to reduce cardiovascular morbidity and mortality: a review of the evidence
    Thomas D Giles
    Heart and Vascular Institute, Tulane University School of Medicine, New Orleans, LA, USA
    J Clin Hypertens (Greenwich) 11:512-9. 2009
    ..A large ongoing study is investigating whether therapy with an oral antidiabetic drug or an angiotensin II receptor blocker reduces the incidence of new-onset diabetes and cardiovascular events in high-risk patients...
  18. ncbi request reprint Effects of olmesartan medoxomil on systolic blood pressure and pulse pressure in the management of hypertension
    Thomas D Giles
    Division of Cardiology, Louisiana State University School of Medicine, New Orleans 70112, USA
    Am J Hypertens 17:690-5. 2004
    ..In this analysis, we evaluated the efficacy of the angiotensin II receptor blocker olmesartan medoxomil in reducing systolic blood pressure (SBP) and pulse pressure (PP) in hypertensive patients...
  19. ncbi request reprint The patient with diabetes mellitus and heart failure: at-risk issues
    Thomas D Giles
    Section of Cardiovascular Research, Louisiana State University Health Science Center, New Orleans, Louisiana 70112, USA
    Am J Med 115:107S-110S. 2003
    ..Thus the risk-benefit ratio of using TZDs in patients who have diabetes and heart failure must be carefully considered in this patient population with comorbid disorders...
  20. ncbi request reprint Applying the strategy of combination antihypertensive therapy to special populations
    Thomas D Giles
    Section of Cardiology, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA
    J Clin Hypertens (Greenwich) 8:2-3. 2006
  21. ncbi request reprint Examining therapeutic goals: population versus individual-based approaches
    Thomas D Giles
    Department of Medicine, Louisiana State University School of Medicine, New Orleans, Louisiana 70112, USA
    Am J Hypertens 16:26S-30S. 2003
    ..Ultimately, the treatment decisions should be tailored to each patient, integrating as much information as possible concerning the patient's history, risk, pathophysiology, and lifestyle...
  22. ncbi request reprint A perspective on telmisartan and cardiovascular risk
    Thomas D Giles
    Division of Cardiology, Department of Medicine, Tulane University School of Medicine, New Orleans, Louisiana, USA
    Rev Cardiovasc Med 8:154-9. 2007
    ....
  23. ncbi request reprint Expanding the definition and classification of hypertension
    Thomas D Giles
    Louisiana State University School of Medicine, New Orleans, LA 70112, USA
    J Clin Hypertens (Greenwich) 7:505-12. 2005
    ..We believe it would be preferable to classify all individuals as either normal or hypertensive, based on their cardiovascular evaluation, using the four categories of normal and stages 1, 2, and 3 hypertension...
  24. ncbi request reprint Update on the management of diabetes and hypertension
    Thomas D Giles
    Louisiana State University Medical Center, New Orleans, LA 70112, USA
    J Clin Hypertens (Greenwich) 4:3-10. 2002
  25. ncbi request reprint Relevance of blood pressure variation in the circadian onset of cardiovascular events
    Thomas Giles
    Louisiana State University Health Sciences Center, New Orleans, Louisiana 70112, USA
    J Hypertens Suppl 23:S35-9. 2005
    ..The technique has demonstrated, for example, a significantly greater reduction in blood pressure for the last 6 h of the 24-h dosing interval with telmisartan compared with valsartan...
  26. doi request reprint Pioglitazone and heart failure: results from a controlled study in patients with type 2 diabetes mellitus and systolic dysfunction
    Thomas D Giles
    Tulane University School of Medicine, New Orleans, Louisiana, USA
    J Card Fail 14:445-52. 2008
    ..We compared the effects of pioglitazone and glyburide on cardiac function in patients with type 2 diabetes, systolic dysfunction, and New York Heart Association (NYHA) functional Class II/III HF...
  27. ncbi request reprint Medical management of myocardial ischemia
    Gary E Sander
    Cardiovascular Research Laboratory, Louisiana State University Health Sciences Center, New Orleans, LA 70112 2825, USA
    Am J Geriatr Cardiol 14:205-9. 2005
  28. ncbi request reprint Rationale for combination therapy as initial treatment for hypertension
    Thomas D Giles
    Louisiana State University School of Medicine, New Orleans, LA 70112, USA
    J Clin Hypertens (Greenwich) 5:4-11. 2003
    ....
  29. ncbi request reprint Defining the antihypertensive properties of the angiotensin receptor blocker telmisartan by a practice-based clinical trial
    Thomas D Giles
    LSU School of Medicine, New Orleans, Louisiana, USA
    Am J Hypertens 16:460-6. 2003
    ....
  30. doi request reprint ASH position paper: treatment of hypertension in patients with diabetes-an update
    George L Bakris
    Hypertensive Diseases and Diabetes Center, Department of Medicine, University of Chicago Pritzker School of Medicine, Chicago, IL 60637, USA
    J Clin Hypertens (Greenwich) 10:707-13; discussion 714-5. 2008
    ..Last, an updated algorithm is provided that incorporates many of the new findings and is suggested as a starting point to achieve blood pressure goals...
  31. doi request reprint The need for defining- and redefining- hypertension: beyond the numbers
    Thomas D Giles
    Cardiovascular Research, Louisiana State University School of Medicine, New Orleans, LA 70112, USA
    Postgrad Med 118:21-5. 2005
    ..In this article, Drs Giles and Sander review the current definitions of hypertension in clinical practice and its evaluation in light of total cardiovascular risk...
  32. ncbi request reprint ALLHAT and ANBP2: what have we learned from recent mega-trials?
    Gary E Sander
    Section of Cardiology, Department of Medicine, Louisiana State University Health Sciences Center, New Orleans, LA 70112 2825, USA
    Am J Geriatr Cardiol 12:267-71. 2003
  33. ncbi request reprint Pharmacologic update: treatment of erectile dysfunction in the elderly with phosphodiesterase type 5 inhibitors: cardiovascular implications
    Pradeep Agarwal
    Cardiovascular Research Laboratory, Louisiana State University Health Sciences Center, New Orleans 70112 2825, USA
    Am J Geriatr Cardiol 13:332-5. 2004
  34. ncbi request reprint HOPE in PROGRESS--a tale of two trials: blood pressure reduction or drug mechanism?
    Gary E Sander
    Louisiana State University Health Sciences Center, New Orleans 70112, USA
    Am J Geriatr Cardiol 11:332-3. 2002
  35. ncbi request reprint The endocannabinoid system and cardiovascular risk: pathophysiologic role and developing therapeutic interventions
    Gary E Sander
    Section of Cardiology, Department of Medicine, Tulane Medical Center, New Orleans, LA 70112, USA
    Am J Geriatr Cardiol 15:255-9. 2006
  36. ncbi request reprint Hypertension and lipids: lipid factors in the hypertension syndrome
    Gary E Sander
    Cardiovascular Research Laboratory, Louisiana State University Health Sciences Center, 1542 Tulane Avenue, New Orleans, LA 70112, USA
    Curr Hypertens Rep 4:458-63. 2002
    ..Recognition and identification of multiple risk factors and appropriate treatment in a manner that minimizes excessive oxidative stress is critical to the maintenance of normal endothelial cell function and cardiovascular risk reduction...
  37. ncbi request reprint Renin-angiotensin system modulation for treatment and prevention of cardiovascular diseases: toward an optimal therapeutic strategy
    Thomas D Giles
    Division of Cardiology, Tulane University School of Medicine, New Orleans, Louisiana, USA
    Rev Cardiovasc Med 8:S14-21. 2007
    ..This article examines the results of clinical trials of ACE inhibitors and ARBs and assesses the potential for improving outcomes through a more global inhibition of the RAS with renin inhibitors...
  38. doi request reprint Beta-blocker therapy for patients with ventricular heart failure and reduced systolic function
    Thomas D Giles
    Division of Cardiology, Louisiana State University School of Medicine, New Orleans, LA 70112, USA
    Postgrad Med 114:18-29. 2003
    ..Other agents such as angiotensin II-receptor blockers and mineralocorticoid (aldosterone) receptor antagonists may also be important...
  39. ncbi request reprint Pathophysiologic, diagnostic, and therapeutic aspects of the metabolic syndrome
    Thomas D Giles
    Section of Cardiology, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA
    J Clin Hypertens (Greenwich) 7:669-78. 2005
    ..Glucose-lowering agents may be indicated, and drugs such as metformin and thiazolidinediones, which reduce insulin resistance, should form the basis of therapy. Carefully chosen therapy will effectively improve cardiovascular outcomes...
  40. ncbi request reprint The COMET trial
    Michael R Bristow
    Division of Cardiology, University of Colorado Health Sciences Center, B130, Room 6430, 4200 East Ninth Avenue, Denver, CO 80262, USA
    Congest Heart Fail 11:39-47. 2005
  41. doi request reprint Use of beta-blockers for heart failure in patients with diabetes mellitus
    Thomas D Giles
    Cardiovascular Research Louisiana State University Health Science Center, 1542 Tulane Ave, Rm 331E, New Orleans, LA 70112, USA
    Postgrad Med 112:32-7. 2002
    ..These observations strongly support a role for the use of beta-blockers in patients with both heart failure and diabetes...
  42. doi request reprint ASH Position Paper: Dietary approaches to lower blood pressure
    Lawrence J Appel
    Department of Medicine, Division of General Internal Medicine, Johns Hopkins University, Baltimore, MD 21205 2223, USA
    J Clin Hypertens (Greenwich) 11:358-68. 2009
    ..The current challenge is designing and implementing effective clinical and public health interventions that lead to sustained dietary changes among individuals and more broadly in the general population...
  43. ncbi request reprint Noncardiac drugs and QTc interval prolongation: an often unrecognized risk factor for adverse cardiovascular outcomes
    Gary E Sander
    Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA
    Am J Geriatr Cardiol 11:197-202. 2002
  44. ncbi request reprint Diabetes mellitus and heart failure: basic mechanisms, clinical features, and therapeutic considerations
    Thomas D Giles
    Section of Cardiology, Louisiana State University Health Sciences Center, 1542 Tulane Avenue, New Orleans, LA 70112, USA
    Cardiol Clin 22:553-68. 2004
    ..Such action will result in great benefit for patients by reducing morbidity and mortality and improving quality of life and will reduce the financial burden that is associated with this epidemic disease...
  45. ncbi request reprint Alcohol--a cardiovascular drug?
    Thomas D Giles
    Louisiana State University Health Services, New Orleans, LA 70112, USA
    Am J Geriatr Cardiol 14:154-8. 2005
  46. ncbi request reprint Ximelagatran: light at the end of the tunnel or the next tunnel?
    Gary E Sander
    Section of Cardiology, Department of Medicine, Louisiana State University Health Sciences Center, New Orleans, LA 70112 2825, USA
    Am J Geriatr Cardiol 13:221-4. 2004
  47. ncbi request reprint Diabetes mellitus and heart failure
    Gary E Sander
    Section of Cardiology, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA
    Am Heart Hosp J 1:273-80. 2003
    ....
  48. ncbi request reprint Statin therapy in the elderly-the evidence mounts
    Gary E Sander
    Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA
    Am J Geriatr Cardiol 12:65-7. 2003
  49. pmc Adenoviral gene transfer of endothelial nitric-oxide synthase (eNOS) partially restores normal pulmonary arterial pressure in eNOS-deficient mice
    Hunter C Champion
    Department of Pharmacology, Tulane University Health Sciences Center, 1430 Tulane Avenue, New Orleans, LA 70112, USA
    Proc Natl Acad Sci U S A 99:13248-53. 2002
    ....
  50. doi request reprint Beta-blockers for preventing sudden cardiac death
    Thomas D Giles
    Division of Cardiovascular Research, Louisiana State University School of Medicine, New Orleans, LA 70112, USA
    Postgrad Med 114:30-4. 2003
    ..Clinical evidence reveals the association between beta-blockade and improved survival, and trials explore the role for beta-blockers in the prevention of sudden cardiac death...
  51. ncbi request reprint Myocardial effects of ethanol consumption in the rat with streptozotocin-induced diabetes
    Thomas D Giles
    Section of Cardiology, Department of Medicine, Louisiana State University Health Sciences Center, 1542 Tulane Avenue, New Orleans, LA 70112, USA
    Alcohol Clin Exp Res 26:1128-33. 2002
    ..We studied the effect of low-dose ethanol consumption on cardiac function, geometry, and PKC isoforms in the rat with STZ-induced diabetes...
  52. ncbi request reprint Hypertension and heart failure sine heart failure. The ACC/AHA guidelines: a misadventure in the lexicography of cardiomyopathy and heart failure, particularly for the hypertensive
    Thomas D Giles
    Louisiana State University Medical Center, 1542 Tulane Avenue, Room 331E, New Orleans, LA 70112, USA
    J Clin Hypertens (Greenwich) 5:280-1. 2003
  53. ncbi request reprint Treating stage 2 hypertension
    Thomas D Giles
    University of Miami School of Medicine, Miami, FL 3310, USA
    J Clin Hypertens (Greenwich) 7:464-70. 2005
    ..In this clinical review, hypertension experts utilize a case study to provide a paradigm for treating older patients with stage 2 hypertension...
  54. doi request reprint The Editor's Roundtable: Endothelial dysfunction in cardiovascular disease
    Vincent E Friedewald
    Department of Internal Medicine, The University of Texas Medical School at Houston, Houston, Texas, USA
    Am J Cardiol 102:418-23. 2008
  55. ncbi request reprint Beta-blockers in the treatment of hypertension: new data, new directions
    Michael A Weber
    State University of New York, Downstate Medical College, 450 Clarkson Avenue, Brooklyn, NY 11023, USA
    J Clin Hypertens (Greenwich) 10:234-8. 2008
  56. ncbi request reprint Correlates of pulse pressure reduction during antihypertensive treatment (losartan or atenolol) in hypertensive patients with electrocardiographic left ventricular hypertrophy (the LIFE study)
    Eva Gerdts
    Haukeland University Hospital, Bergen, Norway
    Am J Cardiol 89:399-402. 2002
    ....
  57. ncbi request reprint Roundtable discussion: hypertension in children and adolescents
    Marvin Moser
    Department of Medicine Cardiology, Yale University School of Medicine, New Haven, CT, USA
    J Clin Hypertens (Greenwich) 7:24-30. 2005
    ..Townsend, MD, of the Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA; and Marvin Moser, MD, of the Department of Medicine/Cardiology, Yale University School of Medicine, New Haven, CT...
  58. ncbi request reprint Blood pressure--the better biomarker: delay in clinical application
    Thomas D Giles
    J Clin Hypertens (Greenwich) 9:918-20. 2007
  59. ncbi request reprint Quality of life measured in a practice-based hypertension trial of an angiotensin receptor blocker
    Michael A Weber
    State University of New York Downstate College of Medicine, Brooklyn, NY 11203, USA
    J Clin Hypertens (Greenwich) 5:322-9. 2003
    ..001 for each) with the increases in the GWBI scores. Controlling blood pressure appears to be an important element in improving subjective health perceptions of hypertensive patients...
  60. ncbi request reprint Comparative antihypertensive efficacy of angiotensin receptor blocker-based treatment in African-American and white patients
    George L Bakris
    Department of Preventive Medicine, Rush University Medical Center, Chicago, IL 60612, USA
    J Clin Hypertens (Greenwich) 7:587-95; quiz 596-7. 2005
    ..We conclude that an angiotensin receptor blocker as part of a BP-lowering strategy is effective in previously untreated African-American patients, although a higher proportion will require the use of a diuretic compared with Caucasians...
  61. ncbi request reprint The kidney and cardiovascular risk--implications for management: a consensus statement from the European Society of Hypertension
    Luis Ruilope
    Hypertension Unit, Hospital 12 de Octubre, Madrid, Spain
    Blood Press 16:72-9. 2007
    ....
  62. ncbi request reprint An effectiveness study comparing algorithm-based antihypertensive therapy with previous treatments using conventional and ambulatory blood pressure measurements
    Michael A Weber
    SUNY Downstate Medical School, Brooklyn, NY 11203, USA
    J Clin Hypertens (Greenwich) 8:241-50; quiz 251-2. 2006
    ..A treatment algorithm based on the angiotensin receptor blocker, telmisartan, was confirmed by the blinded end point of ABPM as an efficacious alternative to other antihypertensive regimens in clinical practice...
  63. ncbi request reprint First-step use of fixed-dose combination treatment in stage 2 hypertensive patients: has the time come?
    Michael A Weber
    SUNY Downstate College of Medicine, New York, New York, USA
    J Clin Hypertens (Greenwich) 9:276-84. 2007
  64. ncbi request reprint Hypertensive patients with reduced blood pressure still have hypertension: the role of the hypertension specialist
    Thomas D Giles
    J Clin Hypertens (Greenwich) 9:497-9. 2007
  65. ncbi request reprint The editor's roundtable: revisiting the role of beta blockers in hypertension
    William C Roberts
    Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, Texas, USA
    Am J Cardiol 100:253-67. 2007
  66. ncbi request reprint Clinicians treating hypertension need to mind their "P's" (precision) and "Q's"(quantitation): a lesson from left ventricular hypertrophy regression and atrial fibrillation
    Thomas D Giles
    J Clin Hypertens (Greenwich) 9:314-5. 2007
  67. ncbi request reprint Blood pressure goals for hypertension guidelines: what is wrong with "optimal"?
    Thomas D Giles
    J Clin Hypertens (Greenwich) 8:835-9. 2006
  68. ncbi request reprint The cardiometabolic syndrome and calcium channel blocker combination drugs
    James R Sowers
    Diabetes Research Center, University of Missouri Columbia, Columbia, MO, USA
    J Cardiometab Syndr 2:207-12. 2007
    ..The authors maintained full control of the discussion and the resulting content of this article...
  69. ncbi request reprint Prehypertension--what is it and should it be treated?
    Marvin Moser
    J Clin Hypertens (Greenwich) 8:812-8. 2006
  70. ncbi request reprint Where are we going? Beyond JNC 7
    Thomas D Giles
    Prev Cardiol 10:222-7. 2007
    ..Discussants included Suzanne Oparil, MD, University of Alabama at Birmingham, Birmingham, AL, and Thomas G. Pickering, MD, DPhil, Columbia Presbyterian Medical Center, New York, NY...
  71. ncbi request reprint Inhibiting the renin-angiotensin system to prevent cardiovascular diseases: do we need a more comprehensive strategy?
    Michael A Weber
    State University of New York Downstate Medical Center, Brooklyn, NY, USA
    Rev Cardiovasc Med 7:45-54. 2006
    ....
  72. ncbi request reprint Introduction: new directions in hypertension: beyond JNC VI
    Thomas D Giles
    Am J Hypertens 16:25S. 2003
  73. ncbi request reprint Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss
    Paul Poirier
    Quebec Heart and Lung Institute, Sainte Foy, Canada
    Arterioscler Thromb Vasc Biol 26:968-76. 2006
    ..As a whole, overweight/obesity predispose or is associated with numerous cardiac complications such as coronary heart disease, heart failure, and sudden death through its impact on the cardiovascular system...
  74. ncbi request reprint Atherosclerotic renal artery stenosis and renovascular hypertension: clinical diagnosis and indications for revascularization
    Edmund Kenneth Kerut
    Heart Clinic of Louisiana, Marrero, 70072, USA
    J Clin Hypertens (Greenwich) 8:502-9. 2006
    ..Intervention response is variable, but the ongoing Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL) trial, comparing medical therapy with and without stenting, should provide management guidance...
  75. ncbi request reprint ACE inhibitors: over two decades of use
    Domenic A Sica
    Virginia Commonwealth University, Richmond, VA, USA
    J Clin Hypertens (Greenwich) 7:531-7. 2005
    ..Dr. Henry R. Black of Rush University Medical Center, Chicago, IL; and Dr. Vito M. Campese of the University of Southern California, Los Angeles, CA...
  76. ncbi request reprint Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: experiences from MERIT-HF
    Prakash C Deedwania
    Department of Veterans Affairs Medical Center, Fresno, Calif, USA
    Am Heart J 149:159-67. 2005
    ....
  77. ncbi request reprint Alcohol and the cardiovascular system: research challenges and opportunities
    Diane L Lucas
    Division of Metabolism and Health Effects, National Institute on Alcohol Abuse and Alcoholism NIH, Bethesda, MD, USA
    J Am Coll Cardiol 45:1916-24. 2005
    ....
  78. ncbi request reprint Hypertension: definitions and guidelines
    John B Kostis
    University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, New Brunswick, NJ 08903, USA
    J Clin Hypertens (Greenwich) 7:538-9. 2005
  79. ncbi request reprint Pay (adequately) for what works: the economic undervaluation of office and ambulatory blood pressure recordings
    Thomas D Giles
    J Clin Hypertens (Greenwich) 10:257-9. 2008
  80. doi request reprint Beta-blocker therapy in hypertension: a need to pause and reflect
    Thomas D Giles
    J Am Coll Cardiol 51:516-7; author reply 517-8. 2008
  81. ncbi request reprint The ASCOT Trial--are beta-blockers still useful as antihypertensive medication?
    Marvin Moser
    Yale University School of Medicine, New Haven, CT, USA
    J Clin Hypertens (Greenwich) 8:723-8. 2006

Research Grants3

  1. MODERATE ALCOHOL USE--CARDIOVASCULAR RISKS AND BENEFITS
    Thomas Giles; Fiscal Year: 2001
    ..The exacerbation or prevention of EIH will be related to drug effects on the cell-signaling pathway. This research can define the cell-signaling pathway in EIH and provide new and novel approaches to treating EIH. ..